Drug intelligence / Profile preview

BV-TA829

Development stage: Preclinical
Lead developer: BioViva
Modality: Gene Therapies
Administration: Intranasal

Overview

BV-TA829 is a preclinical-stage gene therapy candidate associated with BioViva, a biotechnology company focused on developing regenerative medicines to combat aging and age-related diseases. While the candidate appears in early pipeline documentation, specific details regarding its molecular target, mechanism of action, and primary therapeutic indications have not been publicly disclosed. BioViva's broader research platform utilizes viral vectors, such as adeno-associated virus (AAV) and cytomegalovirus (CMV), to deliver therapeutic genes like TERT (telomerase reverse transcriptase), follistatin, and klotho, which are intended to address cellular senescence and tissue degeneration.

Targets

TERT (Telomerase)KL (Klotho Protein)FST (Follistatin)

Beyond the preview

Go deeper on BV-TA829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BV-TA829.

Explore the full profile